{
    "id": 27383,
    "fullName": "CEACAM5 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "CEACAM5 positive indicates the presence of the CEACAM5 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1048,
        "geneSymbol": "CEACAM5",
        "terms": [
            "CEACAM5",
            "CD66e",
            "CEA"
        ]
    },
    "variant": "positive",
    "createDate": "01/09/2018",
    "updateDate": "01/02/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12664,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GI-6207 demonstrated saety and preliminary efficacy, resulted in stable disease over 3 months in 20% (5/25) of patients with CEA-positive carcinomas (PMID: 24327292).",
            "molecularProfile": {
                "id": 28828,
                "profileName": "CEACAM5 positive"
            },
            "therapy": {
                "id": 6569,
                "therapyName": "GI-6207",
                "synonyms": null
            },
            "indication": {
                "id": 305,
                "name": "carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10571,
                    "pubMedId": 24327292,
                    "title": "Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24327292"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14954,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, SAR408701 treatment resulted in sustained partial response in 25% (3/12) of patients with Ceacam5-positive colorectal cancer, 2 of the responding patients also harbored KRAS mutations (Eu J Cancer Dec 2016, 69(Suppl 1):S14-S15).",
            "molecularProfile": {
                "id": 28828,
                "profileName": "CEACAM5 positive"
            },
            "therapy": {
                "id": 7225,
                "therapyName": "SAR408701",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11840,
                    "pubMedId": null,
                    "title": "First-in-human phase I trial of the anti-CEACAM5 antibody\u2013drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)",
                    "url": "https://www.sciencedirect.com/science/article/pii/S0959804916326302?via%3Dihub"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12665,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GI-6207 treatment resulted in significant immune response at metastasis sites in a patient with CEA-positive thyroid medullary carcinoma (PMID: 24327292).",
            "molecularProfile": {
                "id": 28828,
                "profileName": "CEACAM5 positive"
            },
            "therapy": {
                "id": 6569,
                "therapyName": "GI-6207",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10571,
                    "pubMedId": 24327292,
                    "title": "Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24327292"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28828,
            "profileName": "CEACAM5 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}